Brisbane agbiotech Farmacule BioIndustries has taken a step towards the era of molecular 'pharming' by producing vitronectin, a high-value human protein used in medical research, in genetically modified tobacco plants.

If beauty is skin deep, the latest wrinkle from Brisbane biotech Tissue Therapies (ASX:TIS) should hold deep allure for cosmetics companies -- the company's researchers have developed a live-skin model with the same structure and properties as human skin.

The Queensland government and a consortium of Queensland universities will together invest AUD$5 million in the Melbourne-based Australian Synchrotron.

Protein chemists at Queensland University of Technology (QUT) have produced a new freeze-dried form of Brisbane-based Tissue Therapies' (ASX:TIS) wound-healing technology VitroGro.

A new lab study has shown that Brisbane-based Tissue Therapies' (ASX:TIS) VitroGro technology could stimulate the growth of human skin cells, offering hope for a new treatment for diabetic ulcers, the company said.

The development of nano-sized microcapsules and bioactive bandages to assist in the delivery of the synthetic growth factor complex, VitroGro, is one of 251 projects to be funded in the latest round of the Australian Research Council's (ARC) Linkage Projects scheme.

The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.

Queensland researchers are developing GM cultivars of three tropical crops - pineapple, papaw and banana, to solve disease and quality problems.

Brisbane's Tissue Therapies (ASX:TIS) announced today that trials of its Vitro-Gro wound-healing technology at the Royal Children's Hospital show it not only accelerates the healing of serious burns, but leaves no scarring.

Queensland researchers have made a discovery that could transform the way psychiatrists prescribe anti-psychotic drugs for schizophrenia -- and possibly, for other neuropsychiatric disorders, including depression.

Tissue Therapies (ASX:TIS) has appointed Dr Stephen Mercer -- most recently managing director of Mercy Tissue Engineering -- as its new chief executive.